What is Eyevensys?
Founded in 2008, Eyevensys operates at the intersection of advanced gene therapy and ophthalmology. The company specializes in developing innovative technologies that enable the sustained, localized production of therapeutic proteins within the eye. By bypassing the limitations of traditional eye drops or frequent injections, Eyevensys aims to address a broad spectrum of chronic ophthalmic diseases. Its market position is defined by its clinical-stage status, where it leverages its proprietary platform to transform the standard of care for patients suffering from vision-threatening conditions. The firm's strategic focus remains on clinical validation and the expansion of its therapeutic pipeline, positioning it as a key player in the global biotech landscape.
How much funding has Eyevensys raised?
Eyevensys has raised a total of $43.7M across 3 funding rounds:
Series A
$1.7M
Series B
$30M
Series B
$12M
Series A (2016): $1.7M with participation from Pontifax
Series B (2020): $30M, investors not publicly disclosed
Series B (2021): $12M supported by Korea Investment Holdings
Key Investors in Eyevensys
Pontifax
Pontifax Venture Capital specializes in groundbreaking innovations in life sciences, focusing on transformative healthcare technologies across all development stages.
Korea Investment Holdings
Korea Investment Holdings is a major financial firm and institutional investor specializing in asset management, securities brokerage, and investment banking.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Eyevensys?
Following the recent infusion of capital, Eyevensys is well-positioned to accelerate its clinical development programs and refine its manufacturing capabilities. The company is expected to prioritize the advancement of its lead candidates through late-stage clinical trials, aiming to demonstrate both safety and long-term efficacy in human subjects. As the firm moves toward potential commercialization, strategic focus will likely shift toward regulatory milestones and the establishment of partnerships that can facilitate global market entry. The ongoing support from institutional investors suggests a robust roadmap for scaling operations and potentially exploring new therapeutic indications for its core delivery technology.
See full Eyevensys company page
